Works by Tolcher, A. W.

Results: 24

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
Published in:
2017
By:
- Papadopoulos, K P;
- El-Rayes, B F;
- Tolcher, A W;
- Patnaik, A;
- Rasco, D W;
- Harvey, R D;
- LoRusso, P M;
- Sachdev, J C;
- Abbadessa, G;
- Savage, R E;
- Hall, T;
- Schwartz, B;
- Wang, Y;
- Kazakin, J;
- Shaib, W L
Publication type:
journal article
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Published in:
2017
By:
- Bendell, Johanna C;
- Javle, Milind;
- Bekaii-Saab, Tanios S;
- Finn, Richard S;
- Wainberg, Zev A;
- Laheru, Daniel A;
- Weekes, Colin D;
- Tan, Benjamin R;
- Khan, Gazala N;
- Zalupski, Mark M;
- Infante, Jeffrey R;
- Jones, Suzanne;
- Papadopoulos, Kyriakos P;
- Tolcher, Anthony W;
- Chavira, Renae E;
- Christy-Bittel, Janna L;
- Barrett, Emma;
- Patnaik, Amita
Publication type:
journal article
A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer.
Published in:
Cancer (0008543X), 2010, v. 116, n. 4, p. 814, doi. 10.1002/cncr.24870
By:
- Moulder, Stacy L.;
- Holmes, Frankie A.;
- Tolcher, Anthony W.;
- Thall, Peter;
- Broglio, Kristine;
- Valero, Vicente;
- Buzdar, Aman U.;
- Arbuck, Susan G.;
- Seidman, Andrew;
- Hortobagyi, Gabriel N.
Publication type:
Article
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Published in:
Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1
By:
- Rhoda Molife, L.;
- Li Yan;
- Vitfell-Rasmussen, Joanna;
- Zernhelt, Adriane M.;
- Sullivan, Daniel M.;
- Cassier, Philippe A.;
- Eric Chen;
- Biondo, Andrea;
- Tetteh, Ernestina;
- Siu, Lillian L.;
- Patnaik, Amita;
- Papadopoulos, Kyriakos P.;
- De Bono, Johann S.;
- Tolcher, Anthony W.;
- Minton, Susan
Publication type:
Article
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Published in:
2018
By:
- Goss, Glenwood D.;
- Vokes, Everett E.;
- Gordon, Michael S.;
- Gandhi, Leena;
- Papadopoulos, Kyriakos P.;
- Rasco, Drew W.;
- Fischer, JuDee S.;
- Chu, Katharine L.;
- Ames, William W.;
- Mittapalli, Rajendar K.;
- Lee, Ho‐Jin;
- Zeng, Jiewei;
- Roberts‐Rapp, Lisa A.;
- Loberg, Lise I.;
- Ansell, Peter J.;
- Reilly, Edward B.;
- Ocampo, Christopher J.;
- Holen, Kyle D.;
- Tolcher, Anthony W.;
- Lee, Ho-Jin
Publication type:
journal article
Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapy.
Published in:
BMC Dermatology, 2006, v. 6, p. 7, doi. 10.1186/1471-5945-6-7
By:
- Jones, Kristin;
- Fuller, Clifton D.;
- Luh, Join Y.;
- Childs, Craig C.;
- Miller, Alexander R.;
- Tolcher, Anthony W.;
- Herman, Terence S.;
- Thomas Jr, Charles R.
Publication type:
Article
PI-13.
Published in:
Clinical Pharmacology & Therapeutics, 2006, v. 79, n. 2, p. P10, doi. 10.1016/j.clpt.2005.12.034
By:
- Guo, F.;
- Letrent, S. P.;
- Noe, D. A.;
- Qin, A.;
- Rohrbacher, K. D.;
- Munster, P. N.;
- Tolcher, A. W.;
- Britten, C. D.;
- Gelmon, K.;
- Sharma, A.
Publication type:
Article
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Published in:
2011
By:
- Mita, A C;
- Papadopoulos, K;
- de Jonge, M J A;
- Schwartz, G;
- Verweij, J;
- Mita, M M;
- Ricart, A;
- Chu, Q S-C;
- Tolcher, A W;
- Wood, L;
- McCarthy, S;
- Hamilton, M;
- Iwata, K;
- Wacker, B;
- Witt, K;
- Rowinsky, E K
Publication type:
journal article
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Published in:
Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3
By:
- Stathis, Anastasios;
- Tolcher, Anthony W.;
- Wang, Judy S.;
- Renouf, Daniel J.;
- Chen, Lin-Chi;
- Suttner, Leah H.;
- Freshwater, Tomoko;
- Webber, Andrea L.;
- Nayak, Tapan;
- Siu, Lillian L.
Publication type:
Article
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Published in:
Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7
By:
- Berlin, Jordan;
- Tolcher, Anthony W.;
- Ding, Cliff;
- Whisenant, Jennifer G.;
- Horak, Ivan D.;
- Wood, Debra L.;
- Nadler, Paul I.;
- Hansen, Ulla Holm;
- Lantto, Johan;
- Skartved, Niels Jørgen Ø.;
- Pedersen, Mikkel W.;
- Patnaik, Amita
Publication type:
Article
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Published in:
Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3
By:
- Cleary, James M.;
- Calvo, Emiliano;
- Moreno, Victor;
- Juric, Dejan;
- Shapiro, Geoffrey I.;
- Vanderwal, Carol Ann;
- Hu, Beibei;
- Gifford, Maryella;
- Barch, David;
- Roberts-Rapp, Lisa;
- Ansell, Peter J.;
- Xiong, Hao;
- Ocampo, Christopher;
- Tolcher, Anthony W.
Publication type:
Article
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors.
Published in:
Investigational New Drugs, 2020, v. 38, n. 1, p. 120, doi. 10.1007/s10637-019-00754-y
By:
- Rosen, Lee S.;
- Wesolowski, Robert;
- Baffa, Raffaele;
- Liao, Kai-Hsin;
- Hua, Steven Y.;
- Gibson, Brenda L.;
- Pirie-Shepherd, Steven;
- Tolcher, Anthony W.
Publication type:
Article
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Published in:
Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2
By:
- Goldman, Jonathan W.;
- Rosen, Lee S.;
- Tolcher, Anthony W.;
- Papadopoulos, Kyriakos;
- Beeram, Muralidhar;
- Shi, Peipei;
- Pitou, Celine;
- Bell, Robert;
- Kulanthaivel, Palaniappan;
- Zhang, Xuekui;
- Fink, Aaron;
- Chan, Edward M.;
- Shahir, Ashwin;
- Farrington, Daphne;
- Patnaik, Amita
Publication type:
Article
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Published in:
2020
By:
- Tolcher, Anthony W.;
- Kurzrock, Razelle;
- Valero, Vincente;
- Gonzalez, Rene;
- Heist, Rebecca S.;
- Tan, Antoinette R.;
- Means-Powell, Julie;
- Werner, Theresa L.;
- Becerra, Carlos;
- Wang, Chenxi;
- Leonowens, Cathrine;
- Kalyana-Sundaram, Shanker;
- Kleha, Joseph F.;
- Gauvin, Jennifer;
- D'Amelio, Anthony M.;
- Ellis, Catherine;
- Ibrahim, Nageatte;
- Yan, Li;
- D'Amelio, Anthony M Jr
Publication type:
journal article
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Published in:
2017
By:
- Tolcher, Anthony;
- Berlin, Jordan;
- Cosaert, Jan;
- Kauh, John;
- Chan, Emily;
- Piha-Paul, Sarina;
- Amaya, Alex;
- Tang, Shande;
- Driscoll, Kyla;
- Kimbung, Richard;
- Kambhampati, S.;
- Gueorguieva, Ivelina;
- Hong, David;
- Tolcher, Anthony W;
- Berlin, Jordan D;
- Piha-Paul, Sarina A;
- Kambhampati, S R Prasad;
- Hong, David S
Publication type:
journal article
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Published in:
2015
By:
- Tolcher, Anthony;
- LoRusso, Patricia;
- Arzt, Jennifer;
- Busman, Todd;
- Lian, Guinan;
- Rudersdorf, Niki;
- Vanderwal, Carol;
- Waring, Jeffrey;
- Yang, Jianning;
- Holen, Kyle;
- Rosen, Lee;
- Tolcher, Anthony W;
- Busman, Todd A;
- Rudersdorf, Niki S;
- Vanderwal, Carol Ann;
- Waring, Jeffrey F;
- Holen, Kyle D;
- Rosen, Lee S
Publication type:
journal article
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Published in:
2015
By:
- Tolcher, Anthony;
- LoRusso, Patricia;
- Arzt, Jennifer;
- Busman, Todd;
- Lian, Guinan;
- Rudersdorf, Niki;
- Vanderwal, Carol;
- Kirschbrown, Whitney;
- Holen, Kyle;
- Rosen, Lee;
- Tolcher, Anthony W;
- Busman, Todd A;
- Rudersdorf, Niki S;
- Vanderwal, Carol Ann;
- Holen, Kyle D;
- Rosen, Lee S
Publication type:
journal article
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α<sub>5</sub>β<sub>1</sub> integrin monoclonal antibody (volociximab) in cancer patients.
Published in:
Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 207, doi. 10.1007/s00280-009-1023-8
By:
- Ng, Chee C.;
- Bai, S.;
- Takimoto, C. H.;
- Tang, M. T.;
- Tolcher, A. W.
Publication type:
Article
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Published in:
Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y
By:
- Chia-Chi Lin;
- Beeram, Muralidhar;
- Rowinsky, Eric K.;
- Takimoto, Chris H.;
- Ng, Chee M.;
- Geyer Jr., Charles E.;
- Denis, Louis J.;
- De Bono, Johann S.;
- Hao, Desiree;
- Tolcher, Anthony W.;
- Rha, Sun-Young;
- Jolivet, Jacques;
- Patnaik, Amita
Publication type:
Article
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Published in:
Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
By:
- Chia-Chi Lin;
- Calvo, Emiliano;
- Papadopoulos, Kyriakos P.;
- Patnaik, Amita;
- Sarantopoulos, John;
- Mita, Alain C.;
- Preston, Glenn G.;
- Mita, Monica M.;
- Rodon, Jordi;
- Mays, Theresa;
- I.-Tien Yeh;
- O'Rourke, Pat;
- Takimoto, Chris H.;
- Dancey, Janet E.;
- Chen, Helen;
- Tolcher, Anthony W.
Publication type:
Article
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Published in:
Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 5, p. 911, doi. 10.1007/s00280-007-0672-8
By:
- Rodon, Jordi;
- Garrison, Mitchell;
- Hammond, Lisa A.;
- de Bono, Johann;
- Smith, Lon;
- Forero, Leonardo;
- Hao, Desirée;
- Takimoto, Chris;
- Lambert, John M.;
- Pandite, Lini;
- Howard, Maria;
- Hongsheng Xie;
- Tolcher, Anthony W.
Publication type:
Article
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Published in:
Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 1, p. 97, doi. 10.1007/s00280-007-0579-4
By:
- Guo, Feng;
- Letrent, Stephen P.;
- Munster, Pamela;
- Britten, Carolyn D.;
- Gelmon, Karen;
- Tolcher, Anthony W.;
- Sharma, Amarnath
Publication type:
Article
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Published in:
Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 2, p. 165, doi. 10.1007/s00280-006-0255-0
By:
- Mita, Monica M.;
- Rowinsky, Eric K.;
- Forero, Leonardo;
- Eckhart, S. Gail;
- Izbicka, Elzbieta;
- Weiss, Geoffrey R.;
- Beeram, Muralidhar;
- Mita, Alain C.;
- de Bono, Johann S.;
- Tolcher, Anthony W.;
- Hammond, Lisa A.;
- Simmons, Paul;
- Berg, Kristin;
- Takimoto, Chris;
- Patnaik, Amita
Publication type:
Article
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Published in:
2003
By:
- Tolcher, A W;
- Gerson, S L;
- Denis, L;
- Geyer, C;
- Hammond, L A;
- Patnaik, A;
- Goetz, A D;
- Schwartz, G;
- Edwards, T;
- Reyderman, L;
- Statkevich, P;
- Cutler, D L;
- Rowinsky, E K
Publication type:
journal article